NO20050016L - Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen - Google Patents
Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismenInfo
- Publication number
- NO20050016L NO20050016L NO20050016A NO20050016A NO20050016L NO 20050016 L NO20050016 L NO 20050016L NO 20050016 A NO20050016 A NO 20050016A NO 20050016 A NO20050016 A NO 20050016A NO 20050016 L NO20050016 L NO 20050016L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- diphenyllazetidinone
- derivatives
- lipid metabolism
- metabolism disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0215579.4A GB0215579D0 (en) | 2002-07-05 | 2002-07-05 | Chemical compounds |
PCT/GB2003/002811 WO2004005247A1 (en) | 2002-07-05 | 2003-07-01 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20050016L true NO20050016L (no) | 2005-03-01 |
Family
ID=9939901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20050016A NO20050016L (no) | 2002-07-05 | 2005-01-03 | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen |
Country Status (21)
Country | Link |
---|---|
US (1) | US7470678B2 (ru) |
EP (1) | EP1521742A1 (ru) |
JP (1) | JP2006501184A (ru) |
CN (2) | CN100528842C (ru) |
AR (1) | AR041185A1 (ru) |
BR (1) | BR0312280A (ru) |
CA (1) | CA2491789A1 (ru) |
GB (1) | GB0215579D0 (ru) |
IL (1) | IL165820A0 (ru) |
IS (1) | IS7648A (ru) |
MX (1) | MXPA04012936A (ru) |
NO (1) | NO20050016L (ru) |
NZ (1) | NZ537124A (ru) |
PL (1) | PL374725A1 (ru) |
RU (2) | RU2333199C2 (ru) |
SA (1) | SA02230379B1 (ru) |
TW (1) | TW200404058A (ru) |
UA (1) | UA78564C2 (ru) |
UY (1) | UY27882A1 (ru) |
WO (1) | WO2004005247A1 (ru) |
ZA (1) | ZA200410340B (ru) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7176193B2 (en) | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
US7176194B2 (en) | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
US7671047B2 (en) | 2002-06-19 | 2010-03-02 | Sanofi-Aventis Deutschland Gmbh | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
DE10314610A1 (de) * | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
WO2005062824A2 (en) * | 2003-12-23 | 2005-07-14 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
WO2005061452A1 (en) * | 2003-12-23 | 2005-07-07 | Astrazeneca Ab | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
ES2435790T3 (es) | 2004-12-03 | 2013-12-23 | Intervet International B.V. | Piperazinas sustituidas como antagonistas de CB1 |
CN101243072A (zh) | 2005-06-20 | 2008-08-13 | 先灵公司 | 用作组胺h3拮抗剂的哌啶衍生物 |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
AR056866A1 (es) * | 2005-06-22 | 2007-10-31 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto |
AR057383A1 (es) * | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
AR057072A1 (es) * | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
WO2007108007A1 (en) * | 2006-03-23 | 2007-09-27 | Unichem Laboratories Limited | A process for the preparation of ezetimibe via a novel intermediate |
JP4880348B2 (ja) * | 2006-04-25 | 2012-02-22 | 壽製薬株式会社 | アズレン誘導体及びそれを有効成分とする血清コレステロール低下剤 |
TW200811098A (en) * | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
CA2668371A1 (en) * | 2006-11-02 | 2008-05-15 | Merck & Co., Inc. | Heterocyclyl-substituted anti-hypercholesterolemic compounds |
EP2133347A4 (en) * | 2007-03-06 | 2010-03-17 | Teijin Pharma Ltd | 1-BIARYLAZETIDINONDERIVATE |
DE102007063671A1 (de) * | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2907230A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
EP2968262A1 (en) | 2013-03-15 | 2016-01-20 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9926269B2 (en) | 2013-12-18 | 2018-03-27 | Rudjer Boskovic Institute | Beta-lactam cholesterol absorption inhibitors |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
CN109369491A (zh) * | 2018-12-10 | 2019-02-22 | 无锡福祈制药有限公司 | 一类新的依替米贝衍生物及其制备方法 |
CN109384700A (zh) * | 2018-12-10 | 2019-02-26 | 无锡福祈制药有限公司 | 一类新的依折麦布类似物及其制备方法 |
CN109293547A (zh) * | 2018-12-10 | 2019-02-01 | 无锡福祈制药有限公司 | 一类新的依折麦布衍生物及其制备方法 |
AU2020221834A1 (en) | 2019-02-12 | 2021-09-02 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2107548T3 (es) | 1991-07-23 | 1997-12-01 | Schering Corp | Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion. |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
AU681419B2 (en) | 1993-07-09 | 1997-08-28 | Schering Corporation | Process for the synthesis of azetidinones |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5627176A (en) | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
CA2191455A1 (en) | 1994-06-20 | 1995-12-28 | Wayne Vaccaro | Substituted azetidinone compounds useful as hypocholesterolemic agents |
WO1996009827A2 (en) | 1994-09-20 | 1996-04-04 | Pfizer Inc. | Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor |
US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
BR9611401B1 (pt) | 1995-10-31 | 2010-08-10 | 2-azetidinonas substituìdas com açúcar úteis como agentes hipocolesterolêmicos, composição farmacêutica e kit contendo as mesmas . | |
AU7472896A (en) | 1995-11-02 | 1997-05-22 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US5919672A (en) | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
JP3640888B2 (ja) | 1998-12-07 | 2005-04-20 | シェーリング コーポレイション | アゼチジノンの合成プロセス |
EP1354604A1 (en) | 1998-12-23 | 2003-10-22 | G.D. Searle LLC. | Combinations for cardiovascular indications |
CN1249250C (zh) | 1999-04-05 | 2006-04-05 | 先灵公司 | 用于制备1-(4-氟苯基)-3(R)-[3(S)-羟基-3-(4-氟苯基)丙基]-4(S)-(4-羟苯基)-2-β丙内酰胺的立体选择性微生物还原反应 |
US6593078B1 (en) | 1999-04-16 | 2003-07-15 | Schering Corporation | Use of azetidinone compounds |
DE10042447A1 (de) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports |
HUP0302269A3 (en) * | 2000-12-20 | 2009-08-28 | Schering Corp | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
JP2004516289A (ja) * | 2000-12-21 | 2004-06-03 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ジフェニルアゼチジノン誘導体、その調製方法、その化合物を含む薬剤およびその使用 |
IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
BR0116325A (pt) * | 2000-12-21 | 2003-10-14 | Aventis Pharma Gmbh | 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios |
AU2002247019C1 (en) | 2001-01-26 | 2017-05-11 | Organon Llc | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
WO2002058696A2 (en) | 2001-01-26 | 2002-08-01 | Schering Corporation | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
JP2004521894A (ja) | 2001-01-26 | 2004-07-22 | シェーリング コーポレイション | 胆汁酸金属イオン封鎖剤およびステロール吸収阻害剤の併用および血管適応症の治療 |
DK1353694T3 (da) | 2001-01-26 | 2008-03-25 | Schering Corp | Kombinationer af ezetimibe med aspirin til behandling af vaskulære tilstande |
CA2434488A1 (en) | 2001-01-26 | 2002-08-01 | Harry R. Davis | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
JP2004523569A (ja) | 2001-03-08 | 2004-08-05 | メルク エンド カムパニー インコーポレーテッド | 抗高血圧薬とコレステロール吸収阻害薬の併用療法 |
DK1373230T3 (da) | 2001-03-28 | 2005-11-07 | Schering Corp | Enantiselektiv syntese af azetidinon mellemprodukter |
ATE345792T1 (de) | 2001-05-25 | 2006-12-15 | Schering Corp | Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit |
HUP0401501A3 (en) | 2001-09-21 | 2012-02-28 | Schering Corp | Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s) |
WO2003026643A2 (en) | 2001-09-21 | 2003-04-03 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
WO2003088962A1 (en) | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
DE10227507A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10227508A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10227506A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US6941867B2 (en) | 2002-07-01 | 2005-09-13 | Special Devices, Inc. | Initiator with a slip plane between an ignition charge and an output charge |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
US6761509B2 (en) * | 2002-07-26 | 2004-07-13 | Jan Erik Jansson | Concrete module for retaining wall and improved retaining wall |
CN1678296A (zh) | 2002-07-30 | 2005-10-05 | 卡里凯昂公司 | 依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法 |
US6960047B2 (en) * | 2002-08-02 | 2005-11-01 | Innovative Technology Application, Inc. | Protection barrier apparatus |
EP1529061B1 (en) | 2002-08-06 | 2008-02-13 | Sanofi-Aventis Deutschland GmbH | Method for isolating an intestinal cholesterol binding protein |
MXPA05004810A (es) | 2002-11-06 | 2005-07-22 | Schering Corp | Inhibidores de la absorcion del colesterol para el tratamiento de la desmielinizacion. |
ES2311806T3 (es) * | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
EP1626954A2 (en) | 2003-05-05 | 2006-02-22 | Ranbaxy Laboratories, Ltd. | Process for the preparation of trans-isomers of diphenylazetidinone derivatives |
WO2004107958A2 (en) | 2003-05-30 | 2004-12-16 | Schering Corporation | Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
US7002008B2 (en) * | 2003-06-16 | 2006-02-21 | Bomi Patel Framroze | Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one |
JP2005015434A (ja) | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
WO2005021495A2 (en) | 2003-08-25 | 2005-03-10 | Microbia Inc. | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
US20070161577A1 (en) * | 2003-08-28 | 2007-07-12 | Martinez Eduardo J | Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones |
EP1522541A1 (en) | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Novel hypocholesterolemic compounds |
AU2004286838A1 (en) | 2003-10-30 | 2005-05-19 | Merck & Co., Inc. | 2-azetidinones as anti-hypercholesterolemic agents |
WO2005042692A2 (en) | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
WO2005046797A2 (en) * | 2003-11-05 | 2005-05-26 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
JP2007520453A (ja) | 2003-11-10 | 2007-07-26 | マイクロビア インコーポレーテッド | 4−ビアリーリル−1−フェニルアゼチジン−2−オン |
AU2003282384A1 (en) | 2003-11-24 | 2005-06-08 | Hetero Drugs Limited | A novel process for ezetimibe intermediate |
AU2004298375A1 (en) | 2003-12-17 | 2005-06-30 | Dainippon Sumitomo Pharma Co., Ltd. | Medicinal compositions and combinations |
WO2005062824A2 (en) | 2003-12-23 | 2005-07-14 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
WO2005061452A1 (en) * | 2003-12-23 | 2005-07-07 | Astrazeneca Ab | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
WO2005062897A2 (en) | 2003-12-23 | 2005-07-14 | Dr. Reddy's Laboratories Ltd. | Polymorphs of ezetimibe and processes for the preparation thereof |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
WO2005066120A2 (en) | 2003-12-30 | 2005-07-21 | Ranbaxy Laboratories Limited | Process for asymmetric synthesis of hydroxy-alkyl substituted azetidinone derivatives |
CA2553769C (en) | 2004-01-16 | 2011-01-04 | Merck & Co., Inc. | Npc1l1 (npc3) and methods of identifying ligands thereof |
EA010373B1 (ru) | 2004-01-20 | 2008-08-29 | Панацея Биотек Лтд. | Фармацевтические композиции, содержащие высшие первичные спирты и эзетимиб, и способ их получения |
DE102004025072A1 (de) | 2004-05-21 | 2005-12-15 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten |
AU2005245124A1 (en) | 2004-05-21 | 2005-12-01 | Sanofi-Aventis Deutschland Gmbh | Method for producing 1,4-diphenyl azetidinone derivatives |
WO2006017257A2 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Azetidinone derivatives |
US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
CA2581596A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
WO2006060808A1 (en) | 2004-12-03 | 2006-06-08 | Teva Pharmaceutical Industries Ltd. | Ezetimibe polymorphs |
CN101119966B (zh) | 2004-12-20 | 2014-08-13 | 默沙东公司 | 合成2-吖丁啶酮的方法 |
IL166149A0 (en) | 2005-01-05 | 2006-01-15 | Hadasit Med Res Service | Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity |
EP1851197A2 (en) | 2005-02-09 | 2007-11-07 | Microbia, Inc. | Phenylazetidinone derivatives |
WO2006102674A2 (en) | 2005-03-24 | 2006-09-28 | Microbia, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
US20070049748A1 (en) * | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
US7498431B2 (en) * | 2005-12-01 | 2009-03-03 | Bomi Patel Framroze | Process for the preparation of chiral azetidinones |
-
2002
- 2002-07-05 GB GBGB0215579.4A patent/GB0215579D0/en not_active Ceased
- 2002-10-14 SA SA2230379A patent/SA02230379B1/ar unknown
-
2003
- 2003-01-07 UA UA20041210110A patent/UA78564C2/uk unknown
- 2003-06-30 TW TW092117830A patent/TW200404058A/zh unknown
- 2003-07-01 WO PCT/GB2003/002811 patent/WO2004005247A1/en active IP Right Grant
- 2003-07-01 JP JP2004518920A patent/JP2006501184A/ja active Pending
- 2003-07-01 NZ NZ537124A patent/NZ537124A/en unknown
- 2003-07-01 CA CA002491789A patent/CA2491789A1/en not_active Abandoned
- 2003-07-01 RU RU2004137279/04A patent/RU2333199C2/ru not_active IP Right Cessation
- 2003-07-01 US US10/519,897 patent/US7470678B2/en not_active Expired - Fee Related
- 2003-07-01 CN CNB038158949A patent/CN100528842C/zh not_active Expired - Fee Related
- 2003-07-01 BR BR0312280-8A patent/BR0312280A/pt not_active IP Right Cessation
- 2003-07-01 PL PL03374725A patent/PL374725A1/xx not_active Application Discontinuation
- 2003-07-01 EP EP03762763A patent/EP1521742A1/en not_active Withdrawn
- 2003-07-01 CN CNA2007101050883A patent/CN101058556A/zh active Pending
- 2003-07-01 MX MXPA04012936A patent/MXPA04012936A/es not_active Application Discontinuation
- 2003-07-04 UY UY27882A patent/UY27882A1/es unknown
- 2003-07-04 AR ARP030102439A patent/AR041185A1/es unknown
-
2004
- 2004-12-16 IL IL16582004A patent/IL165820A0/xx unknown
- 2004-12-22 ZA ZA200410340A patent/ZA200410340B/en unknown
-
2005
- 2005-01-03 NO NO20050016A patent/NO20050016L/no not_active Application Discontinuation
- 2005-01-13 IS IS7648A patent/IS7648A/is unknown
-
2008
- 2008-02-28 RU RU2008107146/04A patent/RU2008107146A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR041185A1 (es) | 2005-05-04 |
WO2004005247A1 (en) | 2004-01-15 |
MXPA04012936A (es) | 2005-05-16 |
PL374725A1 (en) | 2005-10-31 |
BR0312280A (pt) | 2005-04-12 |
CN100528842C (zh) | 2009-08-19 |
CA2491789A1 (en) | 2004-01-15 |
JP2006501184A (ja) | 2006-01-12 |
RU2008107146A (ru) | 2009-09-10 |
AU2003242850A1 (en) | 2004-01-23 |
IS7648A (is) | 2005-01-13 |
RU2004137279A (ru) | 2005-09-10 |
US7470678B2 (en) | 2008-12-30 |
UY27882A1 (es) | 2004-02-27 |
NZ537124A (en) | 2008-03-28 |
GB0215579D0 (en) | 2002-08-14 |
ZA200410340B (en) | 2005-10-20 |
US20050239766A1 (en) | 2005-10-27 |
TW200404058A (en) | 2004-03-16 |
IL165820A0 (en) | 2006-01-15 |
UA78564C2 (en) | 2007-04-10 |
CN101058556A (zh) | 2007-10-24 |
RU2333199C2 (ru) | 2008-09-10 |
SA02230379B1 (ar) | 2008-09-02 |
CN1665783A (zh) | 2005-09-07 |
EP1521742A1 (en) | 2005-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
NO20062583L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
NO20062591L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
NO20076138L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
NO20076254L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
MXPA04007414A (es) | Indoles sustituidos como agonistas alfa-1. | |
NO20076195L (no) | Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer | |
NO20076137L (no) | Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi | |
NO20045103L (no) | Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse | |
NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
NO20076196L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
NO20062135L (no) | Fenylderivater som PPAR-agonister | |
NO20063382L (no) | Nye kinolinderivater | |
NO20051962L (no) | Fenetanolaminderivater for behandling av respiratoriske sykdommer | |
PT1263730E (pt) | Derivados amina para o tratamento de apoptose | |
NO20050828L (no) | lndol-3-svovelderivater | |
DE60224172D1 (de) | Formanilid-derivative als beta2-adrenorezeptor-agonisten | |
NO20006521L (no) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivater | |
BRPI0508107A (pt) | derivados de indazol e composições farmacêuticas contendo os mesmos | |
NO20052730L (no) | Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser | |
NO20052182L (no) | Nye forbindelser | |
NO20053483L (no) | 4-Anilinokinazolinderivater for behandling av unormal cellevekst | |
EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |